Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seletalisib (UCB5857) in Primary Sjögren's Syndrome
NCT02610543Phase 2Terminated
- Sponsor
- UCB
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of seletalisib in primary Sjögren's syndrome, sponsored by UCB. Started Oct 2015; status: terminated.
02
Drugs
seletalisib
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02610543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610543.